Exabis Library
Welcome to the e-CCO Library!
P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P666: Short-term outcomes of adalimumab for patients with Crohn's disease and associated prognostic factors: a multicentre retrospective cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P666: Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases : A Nationwide Population-Based Study in South Korea
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P667: Characterization of a large Hispanic cohort with Inflammatory Bowel Disease across a 25-year span
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P667: Safety of anti-TNF treatment in liver transplant recipients – a meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P667: Standard vs. intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P667: Unmet needs in the management of Inflammatory Bowel Diseases in Egypt
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P667: USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease– results from STEADY study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P668: Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResource
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P668: Does biotin deficiency play a role in the pathogenesis of Inflammatory Bowel Disease? Preliminary results of a cross-sectional study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P668: Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P668: Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P668: Real world use and adverse events of SARs-CoV-2 vaccination in Greek patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P669: Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P669: Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM